Quanterix to Participate in PMWC 2021 COVID-19 Conference
Quanterix Corporation (NASDAQ: QTRX) announced that CEO Kevin Hrusovsky will present at the PMWC 2021 COVID-19 Conference from Jan. 25-27, 2021. Hrusovsky will join a panel discussing COVID-19 tracking methodologies on Jan. 25 at 9:50 a.m. PST. Quanterix is advancing precision health through its digital health solution, Simoa, which enhances early disease detection and treatment methods across various therapeutic areas, including oncology and neurology. Founded in 2007, the company is based in Billerica, Massachusetts.
- Participation in PMWC 2021 COVID-19 Conference raises company visibility.
- Simoa technology offers significant advancements in disease detection and treatment.
- None.
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President of Quanterix, and Founder, Powering Precision Health, Kevin Hrusovsky will present at PMWC 2021 COVID-19 Conference being held Jan. 25-27, 2021. The conference will focus on healthcare challenges and developments brought forth by the COVID-19 pandemic and will address the financial and regulatory considerations relevant to progress.
Hrusovsky will participate in the panel, “Tracking COVID-19 with a System Clinical Approach” at 9:50 a.m., PST, on Jan. 25.
To register for PMWC 2021 COVID-19 Conference, visit: https://www.pmwcintl.com/covid/.
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005452/en/
FAQ
What will Quanterix present at the PMWC 2021 COVID-19 Conference?
When is Quanterix's presentation at the PMWC 2021 Conference?
What is Quanterix Corporation's main technology?
In what areas is Quanterix's technology currently being applied?
Where is Quanterix Corporation located?
